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The human cytomegalovirus (HCMV) UL94 gene product is a herpesvirus-common virion protein that is
expressed with true late kinetics. To identify the important cis- and trans-acting factors which contribute to
UL94 transcriptional regulation, we have cloned, sequenced, and analyzed UL94 promoter function by tran-
sient transfection analysis. Transfection of UL94 promoter-reporter gene constructs into permissive human
fibroblasts or U373(MG) cells indicated that promoter activity was detected following infection with HCMV.
Point mutations within a TATA-like element located upstream of the RNA start site significantly reduced UL94
promoter activity. Deletion mutagenesis of the promoter indicated that a positive regulatory element (PRE)
was likely to exist downstream of the UL94 mRNA start site, while a negative regulatory element (NRE) was
present upstream of the TATA box. At late times of infection, the PRE appeared to have a dominant effect over
the NRE to stimulate maximum levels of UL94 promoter activity, while at earlier times of infection, no activity
associated with the PRE could be detected. The NRE, however, appeared to cause constitutive down-regulation
of UL94 promoter activity. Binding sites for the cellular p53 protein located within the NRE appeared to
contribute to NRE function, and NRE function could be recapitulated in cotransfection assays by concomitant
expression of p53 and HCMV IE2-86 protein. Our results suggest a novel mechanism by which the cellular
protein p53, which is involved in both transcriptional regulation and progression of cellular DNA synthesis,
plays a central role in the regulation of a viral promoter which is not activated prior the onset of viral DNA
replication.
Human cytomegalovirus (HCMV) is a member of the beta
class of human herpesviruses and is associated with a number
of serious medical conditions, particularly in individuals with
compromised immune systems (3). Its genome is the largest of
the human herpesviruses (240 kb) and has the capacity to
encode over 200 distinct viral gene products (7). Results from
a number of different laboratories have indicated that two of
these gene products, the major immediate-early (IE) gene
products of HCMV (IE1-72 and IE2-86), are essential viral
proteins that regulate expression of a variety of viral and het-
erologous genes at the level of transcription (4, 9, 31, 32, 43, 47,
54, 58, 59). IE1-72 and IE2-86 have been demonstrated to act
synergistically to mediate transcriptional activation of several
viral genes of subsequent kinetic classes, including viral early
genes, such as the viral DNA polymerase gene (and other early
genes), as well as early-late genes, such as pp65 (1, 37, 38).
Both IE1-72 and IE2-86 have the capacity to regulate tran-
scription from viral and cellular promoters through interac-
tions with cellular activator proteins, such as E2F, p53, CAAT-
box-binding factor, CREB-binding factor, and probably others
(10, 24, 31, 44, 48, 73). In vitro evidence also implicates IE2-86
interactions with basal transcription factors, such as TATA-
box-binding protein and TFIIB, in regulation of viral and cel-
lular promoters, including IE2-86 autoregulation of its own
promoter (4, 9, 32, 35, 36, 43, 46, 47, 54, 61, 78).
Despite mounting evidence that the HCMV IE gene prod-
ucts can stimulate expression of a wide variety of viral and
heterologous promoters, evidence also suggests that not all
HCMV promoters are stimulated by the viral IE proteins. The
HCMV true late gene, pp28 (or UL99), is transcribed by a
mechanism that does not appear to require the HCMV IE1-72
or IE2-86 proteins (15). While it is not clear whether UL99 can
be activated by IE1-72 and/or IE2-86 in conjunction with other
viral proteins, cotransfection experiments indicated that
IE1-72 and IE2-86 do not stimulate expression of the promoter
upstream of the 1.6-kb UL99 RNA start site. Because of the
relative promiscuity of the HCMV IE proteins, it is of partic-
ular interest to understand (i) why this or other late promoters
would be refractory to stimulation by the IE gene products and
(ii) what, if any, role is played by the IE proteins in regulating
late promoter expression.
Much of our understanding of the transcription of herpes-
virus late promoters comes from work with the alphaherpes-
virus herpes simplex virus (HSV) (22, 27, 30). In the HSV
system, transient transfection experiments using late promot-
er-reporter constructs have indicated that the structure of viral
late promoters is fairly simple. They contain TATA boxes
and/or initiator elements which direct the transcription start
site. However, in contrast to promoters of other kinetic classes,
very few sequence elements upstream of the TATA box or
RNA start site appear to significantly enhance late promoter
* Corresponding author. Mailing address: 117 Lineberger Compre-
hensive Cancer Center, Campus Box 7295, University of North Caro-
lina at Chapel Hill, Chapel Hill, NC 27599-7295. Phone: (919) 966-
4323. Fax: (919) 966-4303. E-mail: ESHUANG@MED.UNC.EDU.
† Present address: Department of Molecular Biology, Howard
Hughes Medical Institute, Princeton University, Princeton, NJ 08544.
1814
activation. Rather, there appear to be specific sequence ele-
ments located downstream of the RNA start site which interact
with both viral and cellular proteins and act to both enhance
late gene transcription and limit transcription from these pro-
moters to late times of infection. Viral factors such as the ICP4
protein, which appear to enhance HSV late gene expression,
and cellular factors such as the DAS protein, which interact
with sequence elements more proximal to the RNA start site,
appear to play a more significant role in the temporal regula-
tion of late gene expression (22). In addition to these obser-
vations, it has also been suggested that other HSV late pro-
moters are subject to negative regulation at earlier times of
infection. Still other experiments suggest that the simple struc-
ture of late promoters makes them relatively weak with respect
to their ability to compete for viral and cellular transcription
factors. Thus, it is only through increased concentration of the
promoter sequences, via viral DNA replication, that late pro-
moters are capable of successfully competing for factors nec-
essary to initiate transcription. This model may explain why
late promoters are often activated inappropriately at early
times of infection when expressed from bacterial plasmids. It
has also been suggested that late promoters are not accessible
to transcription factors prior to viral DNA replication due to
local chromatin structure; however, recombination of late pro-
moter-reporter gene constructs into regions of the viral ge-
nome that are normally expressed at early times of infection
indicates that late kinetics are maintained; thus, it is not clear
whether local chromatin structure actually plays a role in late
promoter regulation. The available evidence suggests that sev-
eral of these factors—negative regulation at early times of
infection, enhancement at late times of infection, and in-
creased template concentration—are all likely to contribute to
the strict temporal activity of late promoters.
Even less information is available concerning regulation of
the HCMV true late promoters. As mentioned above, the pp28
promoter cannot be stimulated by the HCMV IE1-72 and
IE2-86 proteins (15). Mutagenesis of the pp28 promoter and
analysis by transient transfection or recombinant virus experi-
ments indicate that a region from 240 to 1103 of the pro-
moter (relative to the RNA start site) is capable of recapitu-
lating true late promoter activity (15, 39). The important
sequence elements within this region (other than a likely
TATA box) have not, however, been extensively analyzed.
Analysis of the ICP36 late promoter suggests that a combina-
tion of HCMV activators IE1-72, IE2-86, and TRS-1 stimu-
lates expression of this promoter; however, the significance of
this observation is unclear since the ICP36 promoter also con-
tains two start sites, both of which are also stimulated by a
combination of IE1-72, IE2-86, and TRS-1, that are activated
at early times of infection (42, 63). Indeed, recent evidence
suggests that a variety of HCMV early promoters are stimu-
lated to a greater extent by cotransfection of other viral fac-
tors—including TRS-1—with the HCMV major IE proteins
(33, 37). Thus, it is unlikely that this is a late-specific regulatory
mechanism (15).
Because current data do not allow any general conclusions
regarding HCMV true late promoter regulation to be drawn,
we have investigated the regulation of expression of the
HCMV UL94 gene product. Previous experiments indicated
that UL94-specific transcripts were detected only at late times
of a productive HCMV infection and were sensitive to treat-
ment with ganciclovir, establishing UL94 as a true late gene
product (76, 77). In this study, we provide additional evidence
that UL94 transcription is restricted to late times of infection
and that a region encompassing 2120 to 148 of the UL94
promoter is likely to contain the cis-acting sequences necessary
to impart true late specificity on the UL94 promoter. We also
demonstrate that three important sequence elements within
this region—a TATA box, an upstream negative regulatory
element (NRE), and a downstream positive regulatory element
(PRE)—contribute to regulation of the UL94 promoter. Co-
transfection experiments indicate that the repressive effect of
the NRE can be recapitulated by expression of cellular p53 and
HCMV IE2-86 proteins. Furthermore, this recapitulation re-
quires p53, suggesting that this cellular protein plays a central
role in regulation of the UL94 promoter.
MATERIALS AND METHODS
Cell culture and virus. Human embryonic lung (HEL) cells, human astrocy-
toma cell line U373(MG), and human osteosarcoma cell line Saos-2 were prop-
agated in Dulbecco modified Eagle medium (DMEM) supplemented with 10%
[HEL and U373(MG) cells] or 15% (Saos-2 cells) fetal bovine serum (FBS) as
well as antibiotics. Towne strain HCMV [HCMV (Towne)] was propagated in
HEL cells as previously described (40, 80).
DNA cloning, sequencing, and plasmids. UL94 promoter fragments were
cloned by PCR amplification of the appropriate regions by using Vent DNA
polymerase (New England Biolabs) and a Perkin-Elmer Cetus DNA thermocy-
cler. The 9412 region was generated by amplification from HindIII-digested
HCMV (Towne) genomic DNA. The remaining constructs were amplified from
plasmid pCAT9412. Oligonucleotides were synthesized at the UNC-Chapel Hill
Lineberger Comprehensive Cancer Center Oligonucleotide Facility. All primers
were engineered to contain either HindIII sites (upstream primers) or PstI sites
(downstream primers) by inclusion of the following sequence at the 59 end of
each primer: (NNNN)2AAGCTT for generation of HindIII sites or
(NNNN)2CTGCAG for generation of PstI sites, where the restriction site is
underlined and NNNN corresponds to either ACGT (primers 1 and 2), CGAT
(primers 3 to 8), or GCAT (primers 9 to 15). Each construct was designated by
“94” followed by the numbers of the primer pair used in its amplification. The
HCMV-specific region of each primer and the constructs generated using each
primer are listed in Table 1.
Following amplification, fragments were digested with HindIII-PstI (Promega)
and ligated into HindIII-PstI-digested pCATBasic (Promega). Ligations were
transformed into Escherichia coli DH5a, and ampicillin-resistant clones were
screened by colony hybridization using nick-translated, [32P]dATP-labeled PCR
fragments as described previously (76). Positive clones were grown, and plasmid
DNA was purified by using Qiagen-tip 500 columns (Qiagen). Some promoter-
chloramphenical acetyltransferase (CAT) constructs were analyzed by DNA
sequence analysis using a Sequenase kit (United States Biochemical) as sug-
gested by the manufacturer, while others were analyzed by fluorescence tagging
at the UNC-Chapel Hill Automated DNA Sequencing Facility.
Expression plasmids for HCMV IE2-86 (pcDNA3-IE86) and IE1-72 (pcDNA-
IE72) proteins have been previously described (80). Expression plasmids for
wild-type (pC53-SN3) and mutant (pC53-SCX3) p53 were supplied by Bert
Vogelstein and have also been previously described (5).
Primer extension analysis. UL94 transcripts were analyzed by primer exten-
sion using whole-cell RNA isolated from HCMV-infected HEL cells as described
previously (76). The first UL94-specific primer, UL94-3 (59 CACCACGTCAG
CGTACCAAGTCTGTTC 39), used in these assays has also been previously
described (76). The second primer, UL94-2, which overlaps the UL94 open
reading frame (ORF), has the sequence 59 ATGGCTTGGCGCAGCGGTAT 39.
CAT assays. For infection-transfection experiments, cells were seeded into
35-mm-diameter six-well plates at 3 3 106 cells/well. The following day, cells
were transfected via liposome-mediated transfection using 1,3-dioleoyloxy-2-(6-
carboxyspermyl)propylamide (DOSPER; Boehringer Mannheim). For each 35-
mm-diameter well, 0.5 mg of reporter plasmid along with 0.5 mg of Rous Sarcoma
virus (RSV)–b-galactosidase (b-Gal) or simian virus 40 (SV40)–b-Gal plasmid
was mixed with 4 ml of DOSPER in a final volume of 100 ml of HEPES-buffered
saline (20 mM HEPES, 150 mM NaCl [pH 7.4]). Sixty microliters of the DNA-
liposome complexes was added dropwise to cells cultured with 1 ml of medium.
All transfections were done in triplicate and were allowed to proceed overnight.
The next day, the transfectant was removed; cells were washed once with 2 ml of
DMEM and subsequently infected with HCMV at a multiplicity of infection of
approximately 2 to 5 PFU/cell. Following a 2-h absorption period, 1 ml of
DMEM supplemented with 4% heat-inactivated FBS was added to each 35-mm-
diameter well. For drug block experiments, the medium was supplemented with
10 mM ganciclovir [9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG); Syntex]
and was changed daily. Cells were harvested at the appropriate time point
postinfection in 250 ml of 13 cell lysis buffer (Promega). For CAT assays, cell
extract was mixed with acetylenzyme coenzyme A (Boehringer Mannheim) and
[14C]chloramphenicol (New England Nuclear), and CAT assays were performed
as described previously (83). Samples were standardized by using the Promega
b-Gal enzyme assay system. Assays were carried out as suggested by the manu-
facturer, and absorbance at 420 nm for each sample was determined with a
Beckman DU-70 spectrophotometer.
For cotransfection experiments, 0.1 to 0.5 mg of each effector plasmid was
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added to the transfection mixture along with 0.5 mg of each of the reporter and
standardization plasmids. DNA amounts were standardized by inclusion of the
appropriate amount of plasmid pGEM-7zf(1) (Promega). Transfections were
carried out as described above except that following the transfection, the medium
was replaced with 2 ml of DMEM supplemented with 10% (HEL and
U373(MG) cells) or 15% (Saos-2 cells) FBS. At 72 h posttransfection, cells were
harvested and CAT assays were performed as described above.
EMSA. For p53 electrophoretic mobility shift assays (EMSA), we used purified
baculovirus-expressed p53 protein with a six-histidine tag (57). Complementary
oligonucleotides containing either wild-type or mutated p53-binding sites from
the UL94 promoter were annealed to generate double-stranded probes. Se-





GGAATCGCGCCGTCAT; and 94p53m2, ATGACGGCGCGATTCCCAAAC
AACGCGCCAGGAGCGATTCCGTGA.
EMSA were performed as previously described (40) except that 13 binding
buffer consisted of 10% glycerol, 25 mM HEPES (pH 7.6), 50 mM NaCl, 1 mM
dithiothreitol, 0.5 mg of bovine serum albumin/ml, 0.1% Triton X-100, and 0.1 mg
of poly(dI-dC)/ml. For antibody supershift experiments, reactions were per-
formed with 1 ml of antibody per 15 of ml reaction mixture for 30 min at room
temperature prior to addition of the probe. Anti-p53 antibodies 421 and DO-1
were obtained from Calbiochem Oncogene Research Products.
RESULTS
Late-specific RNA start site usage in UL94 transcription.
We previously reported that UL94-specific DNA probes de-
tected two classes of transcripts of approximately 9.1 and 2.0 kb
in Northern blot analysis of HCMV-infected cell RNA (76,
77). Both transcript classes could be detected only at late times
of infection and were sensitive to treatment with ganciclovir,
suggesting that UL94 was a member of the true late kinetic
class. We also mapped a putative RNA start site upstream of
the UL94 ORF (76). This start site, located 336 nucleotides
(nt) upstream of the UL94 initiation codon, was positioned 30
bp downstream of a TATA-box-like sequence and was de-
tected by using RNA isolated from HCMV-infected cells at
72 h postinfection (hpi). To ascertain whether this start site was
utilized exclusively at late times of infection, we performed
primer extension analysis on RNA isolated from HCMV-in-
fected cells at IE, early, and late times of infection, as well as
RNA from mock-infected cells and HCMV-infected cells
treated with ganciclovir, using a UL94-specific primer that was
utilized in our previous RNA mapping experiments. As dem-
onstrated in Fig. 1, extension of the primer to the putative
RNA start site could be detected only at 72 hpi in the infection
time course; in addition, no initiation of transcription at this
site was detected at 72 hpi in the presence of ganciclovir or in
mock-infected cells. Results consistent with those shown in
Fig. 1 were also obtained in analyses using a second primer
(UL94-2) which overlapped the UL94 ORF. These results
confirm our previous observations that UL94-specific mRNA
can be detected only at late times of infection and also dem-
onstrate that the previously mapped UL94 transcript start site
is utilized exclusively at late times of infection.
FIG. 1. Late-specific utilization of the mRNA start site immediately up-
stream of the UL94 ORF, determined by primer extension analysis of UL94
mRNA from HCMV (Towne)-infected fibroblasts using primers UL94-3 (A),
located 208 nt upstream of the UL94 ORF, and primer UL94-2 (B), which
overlaps the ATG for UL94 ORF. The relative positions of the two probes with
respect to the UL94 ORF are shown. The concentration of DHPG was 10 mM.
TABLE 1. Primers and constructs used
Primer HCMV-specific region (59-39) Used for amplification of:
Upstream (HindIII ends)
1 GCTGATTCGCGCCGTGCGCGACGAGATC 9412–9415, 94115
6 GTTTGGGAACTTTGCCGTC 9436







3 GCACCCCGGCTCAGACGAGG 9413, 9436–9439, 94310, 94313
4 GCGCACCACGTCAGCGTACC 9414, 9447
5 GAGAGCCAACGTCGCAGGCG 9415
15 GCGCCGAGCGCTC 94115
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UL94 promoter sequence analysis. To begin to understand
how UL94 transcription is regulated, we sequenced a 525-bp
region proximal to the TATA-box-like element located up-
stream of the UL94 ORF. The sequence analyzed included
approximately 210 bp upstream of the UL94 RNA start site as
well as 335 bp of sequence located between the RNA start site
and the predicted UL94 initiation codon. The results (Fig. 2)
are presented in comparison to the published sequence for
HCMV strain Ad169 in this region (7). We observed only
minor differences in nucleotide sequence between Towne and
Ad169 in the putative UL94 promoter region. The likely
TATA box at 230 is nonconsensus but is consistent in se-
quence with TATA-like elements found in other HCMV pro-
moter regions. As in other HCMV early and late promoters,
single consensus binding sites for several cellular transcription
factors, including Sp1 and c-Myc, are located immediately up-
stream of the TATA box (15, 31). In addition, a possible 20-nt
p53 binding element (with the two 10-nt half-sites separated by
13 nt of intervening sequence) is located in the upstream re-
gion. The upstream-most p53 half-site is a perfect match with
the consensus p53-binding sequence WWWCATGRRR, while
the downstream half-site has a 2-nt mismatch. The sequence
and arrangement of these elements is consistent with that
observed for cellular promoters which have been demonstrated
to be regulated by p53 (18, 20).
Analysis of sequences located downstream of the UL94
RNA start site showed no additional TATA-like elements were
found in this region, although we did detect several consensus
initiator elements (YYAN[T/A]YY). We have thus far, how-
ever, been unable to detect transcription initiation at any of
these sites, suggesting that the presence of these elements is
completely fortuitous. No cis-regulatory sequence (crs)-like or
other binding sites for the HCMV IE2-86 viral transactivator
could be found in the UL94 promoter region. However, se-
quence elements for cellular transcription factors E2F, Sp1,
CREB, and the TATA box have been demonstrated to medi-
ate virus-induced transcription of viral and heterologous pro-
moters, suggesting that these elements, or others, could play a
role in regulation of UL94 transcription (41, 48, 74, 80).
Functional analysis of UL94 promoter sequences. To exam-
ine the ability of the putative UL94 promoter sequences to
direct transcription, we subcloned the 525-bp fragment se-
quenced as described above into reporter vector pCATBasic.
Human fibroblasts were transfected with the resultant plasmid
(9412CAT) and subsequently infected or mock infected with
HCMV. As shown in Fig. 3A, extracts from 9412CAT-trans-
FIG. 2. DNA sequence analysis of the UL94 promoter region from HCMV
(Towne). All bases are identical to the reported sequence for the same region of
HCMV (Ad169), except where indicated, below the Towne sequence. Also
shown are the putative UL94 TATA box and RNA start site (11), as well as
consensus binding sites (boxed) for cellular transcription factors.
FIG. 3. Transient transfection analysis of UL94 promoter activity from reporter construct 9412CAT, containing the full-length UL94 promoter region. UL94
promoter-CAT (9412CAT) or the parent vector (pCATBasic), lacking enhancer-promoter sequences, was transfected into HEL (A) or U373(MG) (B) cells.
Twenty-four hours later, cells were infected (72 hpi) or mock-infected (mock) with HCMV (Towne). Cell lysates were prepared at 72 hpi and assayed for CAT activity.
Shown is the mean percent acetylation from triplicate samples for each time point and plasmid. Samples were standardized for transfection efficiency by determining
b-Gal activity from a cotransfected RSV–b-Gal plasmid.
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fected fibroblasts contained significantly higher CAT activity
following a 72 h superinfection with HCMV relative to mock-
infected cells or infected cells which were transfected with the
parent vector lacking promoter sequences. These results indi-
cated that the 525-bp UL94 promoter fragment contains a
functional promoter that is activated in a virus-dependent
manner.
As a comparison to UL94 promoter activity in fibroblasts, we
repeated the experiment with the HCMV permissive human
astrocytoma cell line U373(MG) and obtained results analo-
gous to the results obtained with fibroblasts (Fig. 3B) (13, 49,
56). It is worth noting that in quantitative comparisons be-
tween fibroblasts and U373(MG) cells, we generally observed
higher levels of UL94 promoter activity in U373(MG) cells. A
comparison of the transfection efficiencies of HEL and
U373(MG) cells by in situ staining for b-Gal activity, following
transfection with an RSV–b-Gal vector, indicated that
U373(MG) cells were transfected at a significantly higher fre-
quency than the HEL cells and with much less variability. Since
U373(MG) cells are fully permissive for HCMV infection and
are more efficiently transfected, we often used these cells pref-
erentially in subsequent transfection-infection experiments.
However, many experiments were also reproduced in HEL
cells to ensure that the results were consistent within the con-
text of normal human cells.
Deletion analysis of the UL94 promoter. To more precisely
define the important functional regions of the UL94 promoter,
we generated a series of deletion mutants of the original
525-bp construct and analyzed the ability of these constructs to
support expression of CAT in transfection-infection experi-
ments. As can be seen in Fig. 4A, deletion of sequences be-
tween 1130 and 1335 resulted in no substantial loss in CAT
activity as measured at 72 hpi in U373(MG) cells. In contrast,
deletion of sequences between 12 and 1130 resulted in at
least a 60% reduction in CAT activity relative to the full-length
construct. The relative decrease in activity observed between
constructs 9414CAT and 9413CAT (i.e., 3-fold) is identical to
the reported decrease in activity of HCMV DNA polymerase
promoter-reporter constructs following deletion of the essen-
tial IR1 sequence element and analysis by transient transfec-
tion-infection (38). Thus, these results suggest that while se-
quences between 1130 and 1335 of the UL94 promoter
region do not contribute significantly to the activity of the
UL94 promoter, a putative positive regulatory region is located
between 12 and 1130.
To examine the influence of sequences upstream of the
TATA box on UL94 promoter activity, we also created a series
of 59-deletion mutants, as shown in Fig. 4B. To minimize any
confounding effects of the downstream positive regulatory re-
gion mapped above, we initially constructed a series of 59-
deletion constructs which extended only to the RNA start site
and thus did not include the downstream regulatory region. As
shown in Fig. 4B, when these constructs were analyzed by
transfection-infection of U373(MG) cells, no significant CAT
activity was observed in mock-infected cells; in addition, we
observed a relatively low CAT activity from constructs contain-
ing 210 or 120 bp of upstream sequence. However, deletion of
all sequences upstream of the TATA box (9137CAT) resulted
in CAT activity at least threefold greater than for constructs
which contained 120 bp or more of upstream sequence. The
FIG. 4. Deletion and point mutation analysis suggests that three important regulatory elements located within 130 bp of the UL94 mRNA start site affect UL94
promoter activity: a 39 PRE, a 59 NRE, and a TATA box. (A) Progressive deletions in downstream sequences (with respect to the RNA start site); (B) progressive
deletions in the upstream region, as well as point mutations in the TATA box. All constructs were generated by subcloning the regions shown in the diagram into
pCATBasic. Plasmids were transfected into U373(MG) cells and subsequently infected with HCMV (Towne) or mock infected. The relative activity determined for
triplicate samples of each construct following standardization by b-Gal activity is shown.
1818 WING ET AL. J. VIROL.
CAT activity from this minimal construct was similar to that
observed with the 9414CAT construct, which contained 210 bp
of upstream sequence as well as the putative downstream reg-
ulatory region. Since addition of 120 bp of upstream sequence
resulted in diminished CAT activity relative to the minimal
construct containing only the region immediately proximal to
the TATA box and RNA start site, this experiment suggested
that a possible negative regulatory region is located upstream
of the TATA box in the UL94 promoter.
To demonstrate that the TATA sequence found in our pro-
moter-CAT constructs was indeed a TATA box, we created a
minimal promoter construct (94310CAT) in which specific
point mutations were introduced into the TATA sequence
(TATTATTAA to TAGGAGTAA). As shown in Fig. 4B, the
level of CAT activity from this construct was threefold lower
than that of the otherwise identical wild-type construct (com-
pare 94310CAT and 9437CAT). This reduction in CAT activity
is similar to that observed in constructs which contain a wild-
type TATA box and the putative 59 NRE, indicating that the
wild-type TATA sequence is essential to maximum promoter
activity.
To determine the effect of the putative 39 PRE on promoter
activity, with or without the presence of the 59 NRE, we cre-
ated an additional construct which contained no sequences
upstream of the TATA box but extended 3 to 1130 (i.e., into
the PRE). As shown in Fig. 5, there was no significant differ-
ence in CAT activity between constructs 9447CAT and
9437CAT at 72 hpi. This finding suggested that the PRE region
did not significantly add to the promoter activity that was
observed with the TATA box alone at late times of infection.
In contrast to these results, however, CAT activity from con-
struct 9414CAT, containing the TATA box, PRE, and NRE,
was significantly higher at 72 hpi than the activity of construct
9413CAT, which contains only the TATA box and NRE. These
results suggested that the positive effect of the PRE is domi-
nant over the negative effect of the NRE at late times of
infection.
Taken together, the results of this series of 59- and 39-dele-
tion constructs, as well as the TATA-box point mutants, sug-
gests the existence of three important regulatory elements
within a region encompassing 2120 to 1130 of the UL94
promoter: a 59 NRE, a 39 PRE, and a TATA box. At late times
of infection, the repressive effect of the 59 NRE is observed
only when the 39 PRE is absent, indicating that PRE function
is dominant to NRE function at late times of infection. How-
ever, constructs which contain only the TATA box and the 59
NRE exhibit only minimal activity in comparison to the TATA-
only construct or constructs containing the 39 PRE. Thus, the
PRE appears to function as a derepression element, as it has
the capacity to overcome the negative effect exerted by the
NRE on the TATA box region of UL94 promoter at late times
of infection.
UL94 promoter activity at 24 hpi and in the presence of
ganciclovir. True late viral promoters are active only after the
onset of viral DNA replication. Deletion mutagenesis of late
promoters from HSV has suggested that in addition to the
requirement for viral DNA replication, cis-regulatory se-
quences located in late promoters influence promoter activity
by either enhancing activity exclusively at late times of infec-
tion or by preventing late promoter activity at earlier times of
infection (19, 21, 22, 27, 29, 30). Indeed, it is likely that both
positive and negative regulatory mechanisms are necessary for
precise regulation of late promoters. To address this question,
we performed another series of transfection-infection experi-
ments in which CAT activity was measured following a 24-h
infection with HCMV or a 72-h infection in the presence of
ganciclovir. Specifically, we compared the activity of our pro-
moter construct containing only the TATA box (9437CAT)
with those of constructs containing the TATA box and either
the NRE (9413CAT), the PRE (9447CAT), or both (9414CAT)
at both 24 hpi and at 72 hpi in the presence of ganciclovir. As
can be seen in Fig. 5B, none of the UL94 promoter constructs
had significant CAT activity at 24 hpi, as directly compared to
the activity of the promoterless-vector control. There was a
small but measurable increase in activity with constructs
9437CAT and 9447CAT, in comparison to the other con-
structs, suggesting that lack of the NRE resulted in higher
activity of the UL94 promoter at early times of infection. This
conclusion was substantiated by the results obtained at 72 hpi
with ganciclovir: constructs 9437CAT and 9447CAT had sig-
nificantly higher activity under these conditions than either
9413CAT or 9414CAT; indeed, the activity of 9413CAT and
9414CAT was no higher at 72 hpi with ganciclovir than at 24
hpi. Interestingly, whereas at 72 hpi the activity of 9414CAT
FIG. 5. (A) The putative downstream PRE is dominant to the upstream
NRE at late times of infection. (B) The dominant effect of the PRE over the
NRE is not obviously observed prior to the onset of viral DNA replication (24
hpi) or if viral DNA replication is inhibited (72 hpi 1 DHPG [10 mM]). Shown
are the relative CAT activities of triplicate samples for each plasmid construct
standardized by b-Gal activity. Transfection-infection was carried out in
U373(MG) cells, and cells were harvested at 24 or 72 hpi as indicated. (C)
Constructs containing the UL94 TATA box as well as the PRE (9447CAT), the
NRE (9413CAT), both elements (9414CAT), or neither element (9437CAT).
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was equivalent to that seen with 9447CAT or 9437CAT (Fig.
5A), its activity at 24 hpi and at 72 hpi with ganciclovir was
extremely low. This suggests that the dominant effect of the
PRE is a late-phase-specific event, since we do not observe the
derepression at 24 hpi or at 72 hpi with ganciclovir. In addition,
since both 9437CAT and 9447CAT, which lack the NRE, are
active both at 24 hpi and at 72 hpi with ganciclovir, it is likely
that the UL94 promoter TATA box can be activated at early
times of infection in the absence of the NRE.
Additional deletion mapping of the 5* NRE. Sequence anal-
ysis of the UL94 promoter demonstrated that putative binding
sites for several cellular transcription factors, including p53,
were located within the NRE region (Fig. 2). It has previously
been reported that whereas p53 generally activates transcrip-
tion in a DNA-binding-dependent manner, in the presence of
viral proteins such as HCMV IE2-86, adenovirus E1A or E1B,
hepatitis B virus (HBV) X protein, or SV40 large T antigen,
transcription from promoters with p53-binding sites is re-
pressed (12, 28, 48, 55, 57, 62, 64, 71, 72). Since the NRE
appears to be involved in repression of the UL94 promoter, we
tested the effect of deletion of either one or both p53 half-sites
on UL94 promoter activity in transfection-infection experi-
ments. There was an additive effect of deletion of either one or
both p53 sites: when both sites were deleted, there was an
approximately 2.5-fold increase in UL94 promoter activity at
72 hpi in comparison to constructs containing the p53-binding-
site region (Fig. 6A). The effect was even more pronounced at
72 hpi with ganciclovir: as much as a fivefold increase in UL94
promoter activity was seen when the region containing the p53
sites was deleted (Fig. 6B). In addition, we detected a close to
twofold increase in promoter activity at late times of infection
when point mutations were introduced into the upstream p53-
binding site (Fig. 6C). These results suggest that the region
containing the p53-binding sites contributes to the repression
activity observed with the UL94 promoter NRE. Since deletion
of the p53-binding sites did not restore promoter activity to
that observed with deletion of the entire NRE, we conclude
that other sequences besides the p53-binding-site region play a
role in full NRE activity.
Effect of p53 on UL94 promoter activity in cotransfection
assays. To determine the effect of p53 on UL94 promoter
activity, we cotransfected p53-negative Saos-2 cells with plas-
mids expressing either wild-type or mutant p53 and UL94
promoter construct 9439CAT, which contains the putative p53-
binding sites. Cotransfection of 9439CAT with wild-type p53
resulted in an approximately 20-fold increase in promoter ac-
tivity compared to cotransfection with mutant p53 or vector
alone controls (Fig. 7A). Likewise, wild-type p53 had no effect
on the promoterless vector control. In addition to promoter
construct 9439CAT, we tested several other UL94 promoter
constructs for responsiveness to p53 in Saos-2 cells (Fig. 7B).
All of the constructs containing both p53-binding sites were
significantly activated by cotransfection with wild-type p53,
whereas constructs lacking the p53-binding sites were not ac-
tivated. Interestingly, construct 9436CAT, which contains only
the downstream, nonconsensus p53-binding site, and construct
94313CAT, which contains point mutations in the upstream
p53-binding site, were also not activated by p53 in Saos-2 cells.
These results imply that both p53-binding sites are necessary
for responsiveness to p53 or, alternatively, that the down-
stream p53 site is simply unresponsive to p53. These two pos-
sibilities are addressed below.
Binding of p53 to the UL94 promoter. To demonstrate bind-
ing of p53 to the UL94 promoter, we used, in EMSA, oligo-
nucleotides containing either one or both UL94 promoter p53-
binding sites, or oligonucleotides containing mutated p53 sites,
and purified baculovirus-expressed p53. As shown in Fig. 8,
p53 bound to the wild-type but not the mutated UL94 p53 sites
(lanes 3 and 4). This binding could be specifically competed by
excess unlabeled wild-type (W3C3) but not mutant (m1/m2)
UL94 p53 site probe (data not shown). We could also super-
shift the p53-UL94 promoter complex with p53-specific anti-
FIG. 6. Deletion or mutation of the consensus p53-binding sites in the putative NRE region leads to increased UL94 promoter activity at late times of infection
or when viral DNA replication is inhibited. (A) CAT activities at 72 hpi for UL94 promoter constructs containing both p53 sites (9413CAT) or with deletions in the
perfect consensus p53 site (9438CAT), both (9436CAT) p53 sites, or all sequences upstream of the TATA box; (B) CAT activities of the same constructs at 72 hpi with
DHPG (10 mM); (C) CAT activities at 72 hpi from constructs containing both (9439CAT) or neither (9437CAT) p53 site, or point mutations in the first perfect
consensus p53 site (94313CAT). The mean relative activity of triplicate samples of each construct, standardized by b-Gal activity, is shown. All constructs were
transfected into U373(MG) cells, infected with HCMV 24 h later, and harvested for CAT activity at 72 hpi.
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bodies (lanes 7 and 8). In addition, p53 protein bound at a
much higher affinity to probes containing both p53 sites (lane
10 [with W3C3 probe]) than a probe containing only the up-
stream consensus p53-binding site (lane 9 [with W2C2]). This
result suggests that binding of p53 to the UL94 promoter
requires both p53-binding sites and is consistent with previous
reports which indicate that binding of tetrameric p53 to re-
sponsive promoters requires more than one 10-bp p53 consen-
sus sequence. These results also suggest that the downstream
p53 site in the UL94 promoter is likely to be necessary for
stabilization of the p53-DNA interaction, despite the fact that
this element alone cannot support p53-mediated transactiva-
tion. It should be noted that while the gel shift and CAT assay
data demonstrate that the two 10-bp p53-binding sites in the
NRE are essential to obtain p53 binding to the NRE (EMSA)
and transactivation (p53 expression alone) or suppression (co-
expression of p53 and IE2-86 [see below]) of NRE-containing
promoters (CAT assays), we have not yet determined which
NRE nucleotides are bound to p53.
Effect of HCMV IE2-86 on the UL94 promoter. Since the
p53-binding sites in the UL94 promoter appear to contribute
to repression of the UL94 promoter during infection, we won-
dered why they mediated p53-dependent activation in Saos-2
cells. As mentioned earlier, the HCMV IE2-86 protein has
been reported to tether a transcriptional repression domain to
p53 through protein-protein interaction (71). The effect of this
interaction is a p53-binding-site-dependent IE2-mediated re-
pression of transcription by p53. To examine the effect of
IE2-86 on p53-mediated activation of the UL94 promoter, we
cotransfected Saos-2 cells with UL94 promoter construct
9439CAT and expression plasmids for both p53 and IE2. As
can be seen in Fig. 9A, IE2-86 alone had no effect on UL94
promoter activity; in contrast, when cotransfected with p53,
IE2-86 abrogated p53-mediated activation of the UL94 pro-
moter. The level of repression that we observed is consistent
with previously published data showing repression of p53-me-
diated transcription by IE2-86. Furthermore, Western blot
analysis showed this repression was not due to a decrease in
p53 levels in the presence of IE2-86 (data not shown). These
results demonstrate that IE2-86-mediated repression of p53
can recapitulate the transcriptional repression observed during
infection by the UL94 promoter NRE region.
Of the functionally important UL94 promoter regions, con-
struct 9439CAT contains only the TATA box and NRE; how-
ever, we also wanted to measure the effect of p53 on promoter
constructs containing the PRE region, since our transfection-
infection data suggested that the PRE had the capacity to
disrupt NRE function at late times of infection. In addition, we
were interested in more precisely localizing the PRE region.
To address the second point, we generated an additional de-
letion mutant, 94115CAT, which extends to 148 with respect
FIG. 7. Stimulation of UL94 promoter activity by p53 in Saos-2 cells. (A)
Saos-2 cells were cotransfected with UL94 promoter construct 9439CAT, con-
taining both p53 sites, or pCATBasic, along with expression plasmids for wild-
type (wt) or mutant (mut) p53. (B) UL94 promoter constructs containing both
p53 sites (9415CAT, 9439CAT, and 9413CAT), neither p53 site (9437CAT and
9436CAT), the downstream nonconsensus p53 site (9438CAT), or point muta-
tions in the upstream perfect consensus p53 site (94313CAT) were cotransfected
with expression plasmid for wild-type p53. For both panels, the relative mean
activity for triplicate samples of each construct and/or condition is shown.
FIG. 8. Binding of baculovirus-expressed p53 to the UL94 promoter p53 sites
by EMSA. (A) Free, labeled, wild-type (wt) (lane 1) or mutant (mut) (lane 2)
oligonucleotide probes, or wild-type (lane 3) and mutant (lane 4) probes incu-
bated with purified, histidine-tagged p53; (B) p53 binding to labeled wild-type
p53 probe containing both p53 sites of UL94 promoter (lane 10, W3C3) com-
pared to only the upstream consensus p53 site (lane 9 and 11, W2C2) as well as
both probes alone (lane 5 and 6, respectively), and supershift/stabilization of p53
binding to UL94 promoter p53 sites with p53-specific antibodies 421 (lanes 7)
and DO-1 (lane 8), respectively.
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to the RNA initiation site. As can be seen in Fig. 9B, when this
construct was tested for functionality in infection-transfection
assays, its activity was similar to that of 9414CAT, which con-
tained an additional 82 bp of downstream sequence. We con-
clude from this experiment that PRE function resides in the
first 48 bp downstream of the RNA initiation site. To deter-
mine the effect of p53 and IE2 on 94115CAT, we cotransfected
Saos-2 cells with 94115CAT and expression plasmids for p53
and IE2-86, as before. The results (Fig. 9C) indicated that
94115CAT is also responsive to p53 and, further, that IE2-86
could abrogate this stimulation. Thus, in the absence of any
other viral gene products, the PRE region of UL94 promoter
has no obvious role in the repression of the UL94 promoter
activity by IE2-86 or p53.
DISCUSSION
In this report, we provide a characterization of the promoter
region regulating expression of the HCMV UL94 protein. We
show that, consistent with our previous data, transcription
from the putative UL94 promoter occurs only at late times of
infection and is sensitive to treatment with the viral DNA
replication inhibitor ganciclovir (77). DNA sequence analysis
of the UL94 promoter indicated the presence of a TATA-box-
like element at 230 with respect to the RNA start site. Anal-
ysis of the UL94 promoter in transient transfection assays
indicated that it could support transcription of CAT during a
productive infection with HCMV. Mutagenesis of the UL94
promoter indicated that maximum activity was dependent on
the TATA box-like element, since point mutations in this ele-
ment significantly reduced UL94 promoter activity. In the ab-
sence of any other UL94 promoter regulatory sequences, this
basic TATA box can activate transcription at early and late
times of infection.
Deletion analysis suggested that regions both upstream and
downstream of the RNA start site are important for regulation
of the UL94 promoter. The downstream PRE region appears
to be necessary for stimulation of UL94 promoter activity at
late times of infection, since in context of the entire promoter,
its absence leads to diminished promoter activity. In contrast,
the upstream NRE appears to prevent activation of the UL94
promoter, since its presence curtails TATA-box-mediated ac-
tivation. The NRE appears to confer constitutive repression on
the UL94 TATA box, since promoter constructs containing
only the NRE and TATA box have diminished activity
throughout infection. In contrast, the PRE appears to enhance
activation of the UL94 promoter exclusively at late times of
infection, since constructs containing both the NRE and PRE
have diminished activity at 24 hpi and at 72 hpi with ganciclovir
but are fully active at 72 hpi. Given these observations, the
primary role of the PRE appears to overcome the repressive
effect of the NRE at late times of infection, since it is only at
late times of infection in the presence of the NRE that any
effect mediated through the PRE can be demonstrated.
Mutagenesis of the PRE region indicated that the function-
ally important sequences were located within the first 48 bp
downstream of the RNA start site. Mutagenesis of the NRE
suggests that its activity is mediated, in part, through two 10-bp
binding sites for the cellular protein p53. Deletion of the p53-
binding sites increased UL94 promoter activity; point muta-
tions in the upstream p53 site had the same effect. Purified p53
protein bound to wild-type but not mutant UL94 promoter p53
binding sites in EMSA. This binding occurred at a much higher
affinity when a probe containing both p53 sites was used.
In addition to these experiments, the biological effect of the
NRE region was recapitulated in cotransfection experiments
using expression plasmids for p53 and HCMV IE2-86 protein
in conjunction with UL94 promoter-CAT constructs. We also
demonstrated that p53 stimulated UL94 promoter activity in
cotransfection assays in a manner dependent on the presence
FIG. 9. IE2-mediated inhibition of p53 transactivation of UL94 promoter
constructs, with or without the PRE region, recapitulates NRE function. (A)
Cotransfection of UL94 promoter construct 9439CAT, which lacks the PRE,
with expression vectors for p53, p53 plus IE2-86, or the empty expression vector
(pCDNA); (B) transfection-infection experiment demonstrating that UL94 pro-
moter construct 94115CAT, which contains an additional deletion in the PRE
region, has levels of activity comparable to those of 9414CAT at late times of
infection; (C) IE2-86-mediated inhibition of p53 transactivation of UL94 pro-
moter construct 94115CAT, containing the reduced PRE region. The relative
mean activity of triplicate samples for each condition is shown in each case.
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of both p53-binding sites. This stimulation was abrogated by
cotransfection with the HCMV IE2-86 protein, suggesting that
a p53-IE2 interaction is important for repression of the UL94
promoter. This effect is consistent with the observed role of the
NRE region in the transfection-infection experiments.
The exact nature of the PRE and NRE regions is unclear,
although it appears that the NRE functions, in part, via inter-
action with cellular p53. As has been seen with other HCMV
viral promoters that contain NRE and PRE regions, constructs
containing only the PRE were constitutively active (31). In
addition, as has been shown with at least one other HCMV
viral promoter (UL4), cellular factors bind to and are impor-
tant for the NRE function, as we have demonstrated with p53
in this study. However, in the UL4 promoter, IE2 expression
could activate gene expression (31), whereas IE2-86 is required
for the NRE region to prevent UL94 promoter activation.
Clearly, there are other important sequences within the NRE,
since deletion of the p53 sites does not result in complete NRE
inactivation. We are currently investigating the role of other
sequences within the NRE, including the Sp1 site. Since p53
has been reported to physically interact with Sp1, it is possible
that a larger complex containing both of these proteins en-
hances NRE function (20).
Both IE2-86 and p53 are rapidly induced and/or their levels
are stabilized throughout HCMV infection (34, 51, 52, 62, 65);
thus, it is likely that an interaction between the two proteins
results in a constitutive inactivation of promoters containing
certain p53 sites during HCMV infection. While no data ad-
dressing this possibility have been published, it has been sug-
gested that levels of the p53-regulated protein p21/WafI/CipI
are not altered during HCMV infection (38). Since other stim-
uli which increase intracellular concentrations of p53 often
lead to a p53-mediated induction of p21 (6, 14, 23), it is likely
that p53, through its interactions with IE2-86, is inactivated
during HCMV infection with respect to its ability to transac-
tivate certain promoters. This effect of IE2-86 on p53 has been
documented in other studies via transient assays using p53-
reporter constructs in cotransfections with p53 and IE2 (65,
74). It has also been reported that p53 and IE2-86 physically
interact to mediate this effect (74). Active repression of p53-
responsive promoters has also been observed in several other
viral systems, including adenovirus, SV40, and HBV; in each
case, the repressive effect is mediated by important viral tran-
scriptional regulators, including adenoviruses E1A/E1B, SV40
large T antigen, and the HBV X protein (28, 55, 64, 67, 68, 70,
75). Since the HCMV IE2-86 protein shares many functional
characteristics with these proteins, it is reasonable to speculate
that it has a similar effect on p53 activity during the viral
replication cycle. In fact, it is likely that induction or stabiliza-
tion of p53 during viral infection ensures that p53-responsive
promoters remain actively repressed during the replication
cycle, in a manner dependent on viral transcriptional regula-
tors. p53 has been well documented to be involved in both cell
cycle arrest and apoptosis (1, 2, 6, 8, 11, 17, 25, 26, 45, 60, 66,
79). Whether the primary goal of the HCMV-mediated inac-
tivation of p53 function is to prevent p53-mediated cell cycle
arrest or, alternatively, p53-mediated apoptosis is not yet clear.
It has been reported that IE2-86 can inhibit apoptosis in cer-
tain cell types and that HCMV infection results in cell cycle
arrest in G2/M (36, 84); both of these effects are possibly
mediated through p53. Regardless of this distinction, our re-
sults suggest that p53 is involved in regulating the UL94 pro-
moter, providing functional relevance, in the context of
HCMV infection, for the interaction between IE2-86 and p53.
While we have identified important cis-regulatory signals
and trans-acting factors which have the capacity to regulate the
UL94 promoter, we have not yet addressed the role of viral
DNA replication. Since the UL94 promoter is not active at
early times of infection or at 72 hpi with ganciclovir in its
normal genomic context, it is clear that viral DNA replication
plays an important role in UL94 promoter regulation. As has
been demonstrated for other herpesvirus late promoters, we
have observed that even those UL94 promoter constructs that
have reduced activity due to mutation are not completely in-
activated in transient transfection experiments. This is likely to
be due to the fact that our promoter constructs are presented
in the context of bacterial plasmids instead of the viral genome:
such a context has been demonstrated to abrogate some as-
pects of viral late gene regulation. The mechanism responsible
for this effect, however, is not known. Now that we have de-
fined a minimal UL94 promoter region that appears to contain
all of the important cis-regulatory regions, we would like to
recombine a UL94 promoter-reporter gene construct into the
viral genome in order to study its regulation in a more appro-
priate context. Such an approach has been used to study HSV
late promoters as well as the HCMV UL99 true late promoter
(20, 22, 39). We anticipate that in the context of the viral
genome, the effects of mutations within the NRE and/or PRE
will be substantially greater than what has been observed in
transient assays and that we will be able to more precisely
define the role of these cis-regulatory regions as well as viral
and cellular proteins in the regulation of UL94 expression.
It is particularly intriguing that a late promoter—whose ac-
tivity requires the onset of viral DNA replication—would be
regulated, in part, through p53. Aside from its role in regulat-
ing transcription of important cell cycle regulators such as p21
and mdm2, p53 can also actively inhibit cellular DNA replica-
tion through protein-protein and protein-DNA interactions
(49). While the role for p53 in HCMV viral DNA replication
has not been demonstrated, regulation of the UL94 promoter
by a cellular protein that can regulate both transcription and
DNA replication is consistent with the association between
viral late gene transcription and viral DNA replication. Thus,
our results suggest a possibly novel mechanism by which viral
DNA replication and late gene expression are concomitantly
regulated.
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